HRP20210098T1 - Postupci i pripravci koji se odnose na upotrebu površinski aktivnih tvari s niskim udjelom hlb u proizvodnji sintetičkih nanonosača koji sadrže rapalog - Google Patents
Postupci i pripravci koji se odnose na upotrebu površinski aktivnih tvari s niskim udjelom hlb u proizvodnji sintetičkih nanonosača koji sadrže rapalog Download PDFInfo
- Publication number
- HRP20210098T1 HRP20210098T1 HRP20210098TT HRP20210098T HRP20210098T1 HR P20210098 T1 HRP20210098 T1 HR P20210098T1 HR P20210098T T HRP20210098T T HR P20210098TT HR P20210098 T HRP20210098 T HR P20210098T HR P20210098 T1 HRP20210098 T1 HR P20210098T1
- Authority
- HR
- Croatia
- Prior art keywords
- value less
- nonionic surfactant
- hlb value
- equal
- carrier material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| EP15798601.9A EP3215133B1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
| PCT/US2015/059349 WO2016073798A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210098T1 true HRP20210098T1 (hr) | 2021-03-05 |
Family
ID=54697646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210098TT HRP20210098T1 (hr) | 2014-11-05 | 2015-11-05 | Postupci i pripravci koji se odnose na upotrebu površinski aktivnih tvari s niskim udjelom hlb u proizvodnji sintetičkih nanonosača koji sadrže rapalog |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20160128987A1 (OSRAM) |
| EP (6) | EP3215133B1 (OSRAM) |
| JP (5) | JP6912377B2 (OSRAM) |
| KR (2) | KR102656139B1 (OSRAM) |
| CN (5) | CN107072964A (OSRAM) |
| AU (4) | AU2015342968B2 (OSRAM) |
| BR (3) | BR122021025344B1 (OSRAM) |
| CA (2) | CA2966850C (OSRAM) |
| CY (1) | CY1124418T1 (OSRAM) |
| DK (4) | DK3215192T3 (OSRAM) |
| EA (2) | EA201790978A1 (OSRAM) |
| ES (4) | ES2865375T3 (OSRAM) |
| FI (2) | FI3834823T3 (OSRAM) |
| HR (1) | HRP20210098T1 (OSRAM) |
| HU (4) | HUE067697T2 (OSRAM) |
| IL (7) | IL283699B (OSRAM) |
| LT (1) | LT3215133T (OSRAM) |
| MX (4) | MX386982B (OSRAM) |
| PL (1) | PL3215133T3 (OSRAM) |
| PT (1) | PT3215133T (OSRAM) |
| RS (1) | RS61359B1 (OSRAM) |
| SI (1) | SI3215133T1 (OSRAM) |
| WO (2) | WO2016073799A1 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
| CN106177940A (zh) | 2010-05-26 | 2016-12-07 | 西莱克塔生物科技公司 | 含有佐剂的合成纳米载体的剂量选择 |
| US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| AU2012249553A1 (en) | 2011-04-29 | 2013-10-24 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| MX2015015231A (es) | 2013-05-03 | 2016-07-06 | Selecta Biosciences Inc | Métodos y composiciones para mejorar las células t reguladoras de cd4+. |
| JP6248263B2 (ja) * | 2013-08-20 | 2017-12-20 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| IL292575A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system |
| US10125378B2 (en) * | 2015-02-17 | 2018-11-13 | San Nopco Ltd. | Additive for bioethanol fermentation process and method for producing bioethanol |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| WO2017156513A1 (en) | 2016-03-11 | 2017-09-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| KR102341902B1 (ko) * | 2016-09-09 | 2021-12-21 | 카오카부시키가이샤 | 디카르복실산 결정 및 그 제조 방법 |
| CN109922819A (zh) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
| WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
| SG11202107922QA (en) * | 2019-01-24 | 2021-08-30 | Generation Bio Co | Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response |
| CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| AU2020284555A1 (en) | 2019-05-28 | 2021-12-23 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| CA3138071A1 (en) | 2019-06-04 | 2020-12-10 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| MX2022004759A (es) * | 2019-10-21 | 2022-08-19 | Selecta Biosciences Inc | Métodos y composiciones para tratar enfermedades y trastornos hepáticos. |
| CN118384281A (zh) | 2019-11-08 | 2024-07-26 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| MX2022010568A (es) | 2020-02-26 | 2022-11-30 | Selecta Biosciences Inc | Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. |
| BR112022018070A2 (pt) * | 2020-03-11 | 2022-10-25 | Selecta Biosciences Inc | Métodos e composições relacionados a nanoveículos sintéticos |
| CN115916193A (zh) * | 2020-04-14 | 2023-04-04 | 西莱克塔生物科技公司 | 用于诱导自噬的方法和组合物 |
| WO2022098901A1 (en) | 2020-11-04 | 2022-05-12 | Selecta Biosciences, Inc. | Compositions for reducing immune responses against immunoglobulin proteases |
| AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| MX2023011930A (es) | 2021-04-09 | 2024-03-11 | Selecta Biosciences Inc | Nanoportadores sintéticos que comprenden un inmunosupresor en combinación con antagonistas del receptor de il-2 de alta afinidad para mejorar la tolerancia inmune. |
| CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| JP2024539646A (ja) | 2021-10-12 | 2024-10-29 | カーティザン セラピューティクス，インコーポレーテッド | ウイルスベクター投薬プロトコル |
| WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| AU2023321906A1 (en) | 2022-08-11 | 2025-03-27 | Cartesian Therapeutics, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| TWI877967B (zh) * | 2023-12-28 | 2025-03-21 | 訊聯生物科技股份有限公司 | 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| AU5068999A (en) | 1998-07-31 | 2000-02-21 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
| DE69930753D1 (de) * | 1998-09-01 | 2006-05-18 | Elan Corp Plc Dublin | Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US20050232984A1 (en) | 2002-08-23 | 2005-10-20 | Heinrich Haas | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| AU2006284657B2 (en) * | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| MX350501B (es) | 2007-10-12 | 2017-09-07 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| US8613951B2 (en) * | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| US8206747B2 (en) * | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| ES2776126T3 (es) * | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| CN103179955B (zh) * | 2010-09-14 | 2016-08-03 | 纳诺洛吉卡股份公司 | 用于不良水溶性的药物和化妆活性成分的过饱和释放赋形剂 |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| AU2012249553A1 (en) * | 2011-04-29 | 2013-10-24 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| AU2012323937A1 (en) | 2011-10-14 | 2014-06-05 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 IL IL295292A patent/IL295292B2/en unknown
-
2017
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
-
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP2021143180A/ja active Pending
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
-
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210098T1 (hr) | Postupci i pripravci koji se odnose na upotrebu površinski aktivnih tvari s niskim udjelom hlb u proizvodnji sintetičkih nanonosača koji sadrže rapalog | |
| JP2017533243A5 (OSRAM) | ||
| JP2021143180A5 (OSRAM) | ||
| Li et al. | In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets | |
| Sermkaew et al. | Liquid and solid self-microemulsifying drug delivery systems for improving the oral bioavailability of andrographolide from a crude extract of Andrographis paniculata | |
| Zhuang et al. | Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability | |
| Gasmi et al. | Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems | |
| KR100717581B1 (ko) | 마이크로 캡슐화 방법 | |
| JP2017537081A5 (OSRAM) | ||
| CN101534796B (zh) | 含有生理活性物质的粒状组合物及其制备方法 | |
| Lei et al. | Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility | |
| JP2016510022A5 (OSRAM) | ||
| Elsayed | Controlled release alginate-chitosan microspheres of tolmetin sodium prepared by internal gelation technique and characterized by response surface modeling | |
| Xia et al. | In vitro evaluation of α-lipoic acid-loaded lipid nanocapsules for topical delivery | |
| Rahman et al. | Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline | |
| Hyma et al. | Formulation and characterisation of self-microemulsifying drug delivery system of pioglitazone | |
| CN103768103B (zh) | 一种蜂胶纳米乳口服液及其制备方法 | |
| Chen et al. | Microfluidic preparation of monodisperse PLGA-PEG/PLGA microspheres with controllable morphology for drug release | |
| Li et al. | Development and evaluation of optimized sucrose ester stabilized oleanolic acid nanosuspensions prepared by wet ball milling with design of experiments | |
| US20160081964A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| WO2015186040A1 (en) | Stable nanoemulsion composition | |
| Bhattacharya | Self-emulsifying drug delivery system (SEDDS) and its pharmaceutical applications | |
| JP2024505623A (ja) | 水難溶性極性溶質用の完全に希釈可能な自己マイクロ乳化デリバリーシステム（ｓｍｅｄｄｓ） | |
| Ammar et al. | Spray dried self-nanoemulsifying drug delivery systems for sertraline HCl: Pharmacokinetic study in healthy volunteers | |
| Ammar et al. | Self-nano emulsifying drug delivery system for sertraline hydrochloride: design, preparation and characterization |